BiVACOR的封面图片
BiVACOR

BiVACOR

医疗设备制造业

Huntington Beach，California 11,896 位关注者

Replacing hearts. Restoring lives.

关注

关于我们

BiVACOR? is a clinical-stage medical device company pioneering the development of a long-term therapy for patients with biventricular heart failure. Under the expert direction of its founder and Total Artificial Heart (TAH) inventor, Daniel Timms, PhD, and the guidance of two luminaries in cardiovascular surgery, William E. Cohn, MD, and O.H. (Bud) Frazier, MD, the BiVACOR TAH is currently undergoing an FDA-approved first-in-human Early Feasibility Study (EFS). Headquartered in Huntington Beach, California, with clinical offices in Houston, Texas, and international offices in Gold Coast, Australia, BiVACOR is committed to addressing the global unmet need of patients with end-stage heart failure awaiting transplant by providing the next generation of life-extending solutions. About the BiVACOR Total Artificial Heart (TAH): The BiVACOR TAH represents a paradigm shift in artificial heart design. The size of the BiVACOR TAH is suitable for most men and women (Body Surface Area >1.4 m2). Despite its small size, the BiVACOR TAH is capable of providing enough cardiac output for an adult male undergoing exercise. Using magnetic levitation technology, the same principle used in high-speed trains, the product features a unique pump design with a single moving part: a magnetically suspended dual-sided rotor with left and right vanes positioned within two separate pump chambers, forming a double-sided centrifugal impeller that propels blood from the respective pump chambers to the pulmonary (lung) and systemic (body) circulations. The TAH has no valves or flexing ventricle chambers, with MAGLEV making pulsatile outflow possible by rapidly cycling the pump's rotor. The non-contact suspension of the rotor via MAGLEV is designed to eliminate the potential for mechanical wear and provide large blood gaps that minimize blood trauma, offering a durable, reliable, and biocompatible heart replacement.

网站
https://www.bivacor.com
所属行业
医疗设备制造业
规模
11-50 人
总部
Huntington Beach，California
类型
私人持股
创立
2008
领域
Rotary Blood Pumps、Biomedical Engineering、Heart Failure、Total Artificial Heart、Artificial Heart、Heart Transplant和Bridge to Heart Transplant

地点

  • 主要

    5432 Bolsa Avenue, Suite A & B

    US，California，Huntington Beach，92649

    获取路线

  • 2450 Holcombe Ave

    US，TX，Houston，77021

    获取路线

  • 16 Nexus Way

    AU，Queensland，Southport，4215

    获取路线

BiVACOR员工

查看全部员工

动态

  • 查看BiVACOR的组织主页
    BiVACOR

    11,896 位关注者

    “We take a personal connection to all of our patients because they’re changing the world for heart failure.” - Daniel Timms, Founder and CTO #TotalArtificialHeart #Innovation

    查看OneVentures的组织主页
    OneVentures

    12,541 位关注者

    We’re incredibly proud of?BiVACOR, who have announced Australia’s first implant of its Total Artificial Heart as a clinical success! ? The patient was the first in the world to be discharged home with the device while awaiting a heart transplant.? ? After 104 days on the?BiVACOR?Total Artificial Heart, he received a donor heart and successfully underwent transplant surgery. He is the longest-supported patient on the device, celebrating another birthday, Christmas and New Year?with his friends and family, free from heart failure symptoms. ? “Being able to bring Australia along this journey and be part of the first clinical trials is immensely important to me and something that I set out to do from the very beginning,” says Dr. Daniel Timms,?BiVACOR?Founder & CTO. ? The?BiVACOR?Total Artificial Heart is designed to replace the native heart's function entirely, acting as a bridge to keep patients alive until a donor heart becomes available.? ? Huge?congratulations?to Daniel Timms, William Cohn, Dr. Paul Jansz, Prof. Chris Hayward, and the teams at?BiVACOR?and St Vincent's Health Australia for their extraordinary work in achieving these milestones. ? Learn more about this Australian-first achievement ?? https://lnkd.in/gDWif272

  • 查看BiVACOR的组织主页
    BiVACOR

    11,896 位关注者

    We are excited to share that the first patient in Australia has been successfully implanted with the BiVACOR Total Artificial Heart and surpassed 100 days with the device and discharged from the hospital before receiving a donor heart. “It is incredibly rewarding to see our device provide extended support to the first Australian patient. The unique design and features of the BiVACOR TAH translate into an unparalleled safety profile, and it’s exhilarating to witness decades of work come to fruition, “ said Daniel Timms, PhD, Founder and CTO of BiVACOR. “The Australian patient is the longest to be supported by the BiVACOR TAH implant while waiting for a heart transplant, allowing him to celebrate another birthday, Christmas, and New Year with friends and family, free from the symptoms of heart failure.” Continued Timms, “The entire BiVACOR team is deeply grateful to the patient and his family for placing their trust in our Total Artificial Heart. Their bravery will pave the way for countless more patients to receive this lifesaving technology.” #TotalArtificialHeart #HeartFailure #MedTech #Innovation

    查看St Vincent's Health Australia的组织主页
    St Vincent's Health Australia

    43,648 位关注者

    Today, we proudly announced a historic medical breakthrough – Australia’s first-ever implant of the BiVACOR Total Artificial Heart. This life changing procedure, performed at St Vincent’s Hospital Sydney, is part of the Monash University-led Artificial Heart Frontiers Program (AHFP), backed by a $50M grant from the Australian Government’s Medical Research Future Fund. The patient holds the record for the longest time a BiVACOR patient has gone from implant to transplant – a major step toward the future of artificial heart technology. With this innovation, the long-term goal is for patients to live with the device indefinitely without needing a transplant. St Vincent’s was the natural choice for this ground breaking surgery – continuing our legacy of heart health innovation, from Australia’s first heart transplant in 1968 to the creation of ‘heart in a box’ technology in 2014. A huge thank you to our partners BiVACOR, Monash University, and all those involved in shaping the future of cardiac care. Together, we’re writing a new chapter in Australian heart health. #ArtificialHeart #TotalArtificialHeart #StVincents St Vincent's Curran Foundation

  • 查看BiVACOR的组织主页
    BiVACOR

    11,896 位关注者

    In the first MedTech Talk episode of 2025, host Geoff Pardo speaks with BiVACOR Chief Medical Officer William Cohn about entrepreneurship, innovation, and thinking outside the box. Dr. Cohn discusses his experiences as a driving force behind the Center of Device Innovation at the Texas Medical Center, what influenced him to pursue medical devices, and finding resources in everyday objects. ???????? ?? ???????????? ????????: https://lnkd.in/eHHaj8Hf #MedTechTalk #innovation #entreprenuer #cardiology #medicaldevice #podcast

    • 该图片无替代文字
  • 查看BiVACOR的组织主页
    BiVACOR

    11,896 位关注者

    The Next Era of Heart Failure Treatment What if we could build a heart that never fails? A human heart is an incredible biological machine, but like any machine, it has limitations: - It wears out. - It can’t be replaced naturally. - It determines how long you live. For decades, attempts have been made to mimic the heart’s natural function with mechanical pumps. But the BiVACOR Total Artificial Heart is taking a different approach: >> Self-regulating blood flow—adapts in real-time to activity levels. >> Rotary pump design—inspired by aerospace engineering and magnetic levitation for durability. >> Designed for long-term function—moving beyond temporary support. We are closer than ever to a future where heart transplants are not the only answer. What do you think will be the most significant shift in cardiac care in the next decade? #HeartMonth #FutureOfMedicine #TotalArtificialHeart #MedicalBreakthroughs #CardiovascularInnovation #OurHearts

    • 该图片无替代文字
  • 查看BiVACOR的组织主页
    BiVACOR

    11,896 位关注者

    The Evolution of Artificial Heart Technology For decades, we’ve had pacemakers, LVADs, and mechanical circulatory support, but a durable, fully functional Total Artificial Heart (TAH) has remained just out of reach. That’s changing. What’s different today: ?? Smaller, more efficient artificial hearts—using aerospace-inspired rotary pump technology. ?? Continuous blood flow design—eliminating wear-and-tear on mechanical valves. ?? Fully implantable systems—working towards removing external drive lines that increase infection risk. The future of heart failure treatment is about more than extending life—it’s about restoring quality of life. #HeartMonth #FutureOfMedicine #CardiovascularInnovation #OurHearts #TotalArtificialHeart

    • 该图片无替代文字
  • 查看BiVACOR的组织主页
    BiVACOR

    11,896 位关注者

    The Heart Transplant Gap: Why It’s Not Enough Every patient with biventricular heart failure is told the same thing: the gold standard is a heart transplant. But what if that’s not an option? The reality of heart transplants: ?? More than 3,500 people in the U.S. are on the heart transplant waitlist each year. ?? Only 3,000 donor hearts become available annually. ?? Many patients won’t survive long enough to receive a transplant. Even for those who do, transplants come with lifelong immune suppression, infection risks, and limited long-term durability. If heart transplants aren’t enough to meet demand, what comes next? That’s the question driving medical device innovation today. Tomorrow, February 7th, is Wear Red Day to bring awareness to the importance of heart health. #HeartFailure #MedicalBreakthroughs #ArtificialHeart #HeartMonth #OurHearts

    • 该图片无替代文字
  • 查看BiVACOR的组织主页
    BiVACOR

    11,896 位关注者

    February is American Heart Month. While heart disease remains the leading cause of death in the U.S., we aim to draw attention to advanced heart disease—specifically, heart failure. Heart failure is one of the most significant challenges in modern medicine, yet many people are unaware of how limited our treatment options currently are. The facts: ?? 6.2 million Americans are living with heart failure today. ?? 1 in 8 deaths in the U.S. is attributed to heart failure. ?? When both sides of the heart fail (biventricular heart failure), the only treatment options are transplant or mechanical support, and donor hearts are in short supply. Despite decades of advancements, we continue to depend on a limited pool of donor hearts to treat a growing population of patients. This month, we’ll delve into the constraints of current treatments and the medical innovations that are shaping the future of heart failure. What do you think is the biggest challenge in treating advanced heart failure today? #HeartMonth #HeartFailure #MedicalInnovation #CardiovascularSolutions #OurHearts

    • 该图片无替代文字
  • 查看BiVACOR的组织主页
    BiVACOR

    11,896 位关注者

    Tomorrow, Dr. William Cohn, BiVACOR’s Chief Medical Officer, will take the stage at ?????????????????????????? & ???????????????? ???? ?????? ?????????????????? ???? ???????????????????????????? ?????????????? to explore ?????? ????????, ??????????????, ?????? ???????????? ???? ?????? ?????????? ???????????????????? ??????????: ?????????????? ???????? ??????????—a deep dive into the evolution of total artificial heart technology and the groundbreaking progress of the BiVACOR Total Artificial Heart. ?? January 31st ? 3:50 – 4:20 PM With decades of advancements leading us closer to revolutionizing heart failure treatment, this is a session you won’t want to miss! https://lnkd.in/gi_KDYHG #ArtificialHeart #MedicalInnovation #Cardiology #HeartFailure #FutureOfMedicine

    • 该图片无替代文字

  • BiVACOR转发了

    查看OneVentures的组织主页
    OneVentures

    12,541 位关注者

    “Imagine a world where someone with end-stage heart failure no longer has to worry about waiting for a transplant.” BiVACOR had an incredible year in 2024, achieving a major milestone by implanting the BiVACOR Total Artificial Heart in five patients as part of an FDA Early Feasibility Study. Ending the year on a high, the FDA approved expanding the trial to an additional 15 patients – a significant step forward in the future of heart failure treatment. We’re proud to back BiVACOR through our Healthcare Fund III, supported by the Biomedical Translation Fund (BTF), and we’re excited to continue this journey alongside them as they achieve more milestones. BiVACOR, Paul Kelly, Department of Industry, Science and Resources

关联主页

相似主页

查看职位

融资

BiVACOR 共 5 轮

上一轮

补助

US$13,000,000.00

在 Crunchbase 上查看更多信息